2,3-二氢-1,4-苯并二噁英-5-硼酸 | 499769-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 2,3-二氢-1,4-苯并二噁英-5-硼酸
• 英文名称: (2,3-dihydrobenzo[b][1,4]dioxin-5-yl)boronic acid
• 英文别名: 2,3-dihydro-1,4-benzodioxin-5-ylboronic acid
• CAS: 499769-88-9
• 化学式: C₈H₉BO₄
• mdl: MFCD03095151
• 分子量: 179.968
• InChiKey: MCWPMXPNJVZOTP-UHFFFAOYSA-N

物化性质

• 沸点：
  372.6±52.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.96
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 安全说明：
  S26,S37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	5-(Dihydroxy-lambda~3~-bromanyl)-2 3-dihydro-1 4-benzodioxine 97% Material Safety Data Sheet
Synonym:
CAS:	499769-88-9

Section 1 - Chemical Product MSDS Name:5-(Dihydroxy-lambda~3~-bromanyl)-2 3-dihydro-1 4-benzodioxine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
499769-88-9	5-(Dihydroxy-lambda~3~-bromanyl)-2,3-d	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Keep refrigerated. (Store below 4C/39F.) Store in a tightly closed container. Store in a dry area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 499769-88-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 135.1 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H9BO4
Molecular Weight: 179.97

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, oxides of boron.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 499769-88-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-(Dihydroxy-lambda~3~-bromanyl)-2,3-dihydro-1,4-benzodioxine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 499769-88-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 499769-88-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 499769-88-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二氢-1,4-苯并二噁英-5-硼酸 在 四(三苯基膦)钯 、 1-羟基苯并三唑 、 silver nitrate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 6.33h， 生成 (R)-2-amino-3-(5-(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)furan-2-carboxamido)propanoic acid trifluoroacetate
  参考文献：
  名称：

  (R)-3-(5-Furanyl)carboxamido-2-aminopropanoic Acid 的衍生物作为具有 GluN2 亚基特异性活性的有效 NMDA 受体甘氨酸位点激动剂

  摘要：

  NMDA 受体介导谷氨酸能神经传递，并且由于它们参与多种精神和神经疾病而成为治疗靶点。在这里，我们描述了一系列 ( R )-3-(5-furanyl)carboxamido-2-aminopropanoic acid analogues 8a – s作为 GluN1 亚基甘氨酸 (Gly) 结合位点激动剂的设计和合成，但不是NMDA 受体的 GluN3 亚基。这些新型类似物以依赖于 GluN2 亚基的方式在 NMDA 受体亚型 (GluN1/2A–D) 中显示出高度可变的效力和激动剂功效。值得注意的是，化合物8p被鉴定为 GluN1/2C (EC 50= 0.074 μM)，相对于 Gly 激活的激动剂功效为 28%，并且在 GluN1/2A、GluN1/2B 和 GluN1/2D 上几乎没有激动剂活性。因此，这些新型激动剂可以通过替代完全内源性激动剂 Gly 或d-丝氨酸 ( d -Ser)来调节特定

  DOI：

  10.1021/acs.jmedchem.1c01810

文献信息

• [EN] QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINE UTILISÉS EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA4BÊTA7
  申请人：GILEAD SCIENCES INC

  公开号：WO2020092375A1

  公开（公告）日：2020-05-07

  The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供了如下所述的化合物的化学式(I)或其药用可接受的盐。本公开还提供了包含化合物的药物组合物的制备方法，制备化合物的方法以及治疗炎症性疾病的治疗方法。
• Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter
  作者：Brian A. Provencher、Amy J. Eshleman、Robert A. Johnson、Xiao Shi、Olga Kryatova、Jared Nelson、Jianhua Tian、Mario Gonzalez、Peter C. Meltzer、Aaron Janowsky

  DOI：10.1021/acs.jmedchem.8b00542

  日期：2018.10.25

  Methamphetamine, a human vesicular monoamine transporter 2 (VMAT2) substrate, releases dopamine, serotonin, and norepinephrine from vesicles into the cytosol of presynaptic neurons and induces reverse transport by the monoamine transporters to increase extracellular neurotransmitters. Currently available radioligands for VMAT2 have considerable liabilities: The binding of [3H]dihydrotetrabenazine ([3H]DHTB)

  甲基苯丙胺是人囊泡单胺转运蛋白2（VMAT2）的底物，可将多巴胺，5-羟色胺和去甲肾上腺素从囊泡释放到突触前神经元的细胞质中，并诱导单胺转运蛋白逆向转运，从而增加细胞外神经递质。当前可用于VMAT2的放射性配体具有相当大的责任：[ 3 H]二氢丁苯那嗪（[ 3 H] DHTB）与VMAT2上一个位点的结合不依赖于ATP，[ 3 H]利血平几乎不可逆地与VMAT2结合。在这里，我们证明了几种芳基哌啶基喹唑啉（APQs）是[ 3的有效抑制剂。H]利血平与HEK-293细胞中表达的重组人VMAT2结合。这些化合物是生物非对映选择性的和生物对映选择性的。铅标记的APQ具有独特性，因为它可逆地与VMAT2结合，但不结合[ 3 H] DHTB结合位点。此外，实验表明，几种新颖的APQ配体具有抑制HEK-VMAT2细胞和小鼠纹状体小泡摄取的高效力，并且可能是表征药物诱导的对人VMAT2表达和功能的作用的有用工具。
• [EN] PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS<br/>[FR] PYRAZOLO[3,4-B]PYRIDINES ET IMIDAZO[1,5-B]PYRIDAZINES UTILISÉES EN TANT QU'INHIBITEURS DE PDE1
  申请人：H LUNDBECK AS

  公开号：WO2019121840A1

  公开（公告）日：2019-06-27

  The present invention provides compounds of formula (I) that are PDEl enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

  本发明提供了化合物(I)的结构，这些化合物是PDEl酶抑制剂，可用作药物，特别是用于治疗神经退行性疾病和精神疾病。本发明还提供了包含本发明化合物的药物组合物以及使用这些化合物治疗疾病的方法。
• An N-Linked Bidentate Phosphoramidite Ligand (N-Me-BIPAM) for Rhodium-Catalyzed Asymmetric Addition of Arylboronic Acids to N-Sulfonylarylaldimines
  作者：Kazunori Kurihara、Yasunori Yamamoto、Norio Miyaura

  DOI：10.1002/adsc.200800631

  日期：2009.1

  A chiral N-linked C2-symmetric bidentate phosphoramidite (N-Me-BIPAM) was newly developed for the rhodium-catalyzed enantioselective addition of arylboronic acids to N-sulfonylimines. This ligand achieved high enantioselectivities in a range of 84–99% ee in additions of arylboronic acids to N-tosyl- and N-nosylarylaldimines.

  手性N-连接的C 2-对称的二齿亚磷酰胺（N -Me-BIPAM）是新开发的，用于铑催化的对N-磺酰亚胺基的芳基硼酸的对映选择性加成。除了在N-甲苯磺酰基和N-壬基芳基醛亚胺中添加芳基硼酸外，该配体还实现了84-99％ee范围内的高对映选择性。
• Novel [4 + 2]-Benzannulation To Access Substituted Benzenes and Polycyclic Aromatic and Benzene-Fused Heteroaromatic Compounds
  作者：Chada Raji Reddy、Uredi Dilipkumar、Motatipally Damoder Reddy

  DOI：10.1021/ol501683v

  日期：2014.7.18

  been developed for the synthesis of aromatic and heteroaromatic compounds through tandem allylic substitution/hydroarylative cycloisomerization process. This method provides a facile and general route to substituted benzenes, naphthalenes, other polycyclic aromatics, and various benzene-fused heteroaromatic compounds such as benzofuran, benzothiophene, indole, and carbazoles.

  已开发出一种常见的[4 + 2]苯乙醛的Morita–Baylis–Hillman乙酸酯与硼酸苯甲酸酯化方法，用于通过串联烯丙基取代/加氢芳基环异构化过程合成芳族和杂芳族化合物。此方法为取代的苯，萘，其他多环芳烃和各种苯稠合的杂芳族化合物（如苯并呋喃，苯并噻吩，吲哚和咔唑）提供了简便而通用的途径。